Small intestinal endocrine cell-derived exosomal ACE2 is associated with amelioration of MASH and may act through suppression of NLRP3 inflammasome activation
Year: 2026
Type: article
Abstract: Background Metabolic dysfunction-associated steatohepatitis (MASH) has emerged as a leading cause of cirrhosis worldwide, with its incidence showing a persistent upward trend. This epidemiological shift is expected to substantially increase the population with metabolic abnormalities complicated by hepatic impairment, thereby posing significant challenges to the efficacy of current therapeutic strategies. Consequently, elucidating the underlying pathophysiological mechanisms has become imperative, with gut-derived exosomes emerging as a focal point in this endeavor. Methods Exosomes were isolated from conditioned medium of STC-1 small intestinal endocrine cells treated with palmitic acid (PA) or bovine serum albumin (BSA). For MASH modeling, PA-stimulated AML-12 hepatocytes and high-fat diet/low-dose streptozotocin-treated mice were employed for in vitro and in vivo studies, respectively. Exosomal interventions were then administered to evaluate their regulatory effects on hepatocyte function under metabolic stress. ACE2 knockout mice were used to delineate the pivotal role of exosomal ACE2. Results ACE2 was found abundantly expressed in STC-1 cell-derived exosomes under physiological conditions(NCEXO). These exosomes were detectable within AML-12 hepatocytes in vitro and showed pronounced hepatic fluorescence accumulation in vivo . In both in-vitro and in-vivo MASH mouse models, NCEXO administration significantly improved hepatocellular function and attenuated hepatic fibrosis. These protective effects may be associated with ACE2-related inhibition of NLRP3 inflammasome activation. Conclusion ACE2-enriched intestinal exosomes accumulate in the liver and may ameliorate MASH partly through suppression of NLRP3 inflammasome activation. Our study extends the conceptual understanding of gut–liver axis regulation and provides new avenues for MASH prevention and therapeutic development.
Source: Frontiers in Pharmacology
Authors: Songtao Yang(Formal analysis, Funding acquisition, Writing – original draft, Writing – review & editing), Jie Cao(Data curation, Methodology, Software, Writing – original draft), Qi Chen(Conceptualization, Data curation, Formal analysis, Writing – review & editing), Fangyu Li(Conceptualization, Formal analysis, Methodology, Writing – review & editing), Yuanyuan Gao(Investigation, Software, Writing – review & editing), Rui Li(Conceptualization, Methodology, Software, Writing – review & editing), Zhuoying Wu(Formal analysis, Resources, Writing – review & editing), Li Yuan(Funding acquisition, Project administration, Supervision, Writing – review & editing)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7233962310
